NCT00004198 2023-12-27
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
Clinical Trials
9 trialsNCT00006478 2023-09-18
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Terminated
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00000105 2017-11-29
Vaccination With Tetanus and KLH to Assess Immune Responses.
Masonic Cancer Center, University of Minnesota
Terminated
NCT00369291 2017-11-29
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT02745756 2017-08-30
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT00004249 2013-06-19
Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003819 2013-03-19
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed